Document Detail


Omeprazole in the treatment of patients with severe reflux oesophagitis not responding to H2-receptor antagonists and ineligible for surgery.
MedLine Citation:
PMID:  2130587     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In 42 patients (25 men, 17 women, mean age 62 years) with severe erosive or ulcerative oesophagitis not responding to H2-receptor antagonist treatment over at least 3 months and ineligible for surgery, omeprazole was administered at an initial dose of 40 mg/day, subsequently reduced to 20 mg after healing of the lesions. Patients had monthly clinical, endoscopic, histological and laboratory assessment over the healing period, then were reevaluated 3-monthly over one year, then 6-monthly, during the maintenance treatment. Stages of oesophagitis were based on the Savary-Miller classification, modified for stage I (erosions must be present). With 40 mg omeprazole, healing was observed in 71%, 83% and 90% of the patients after 1, 2 and 3 months of treatment, respectively. After one month of treatment, a complete healing was less frequently observed in patients with stage IV oesophagitis pre-trial (55%) than in the patients with stages I, II and III pre-trial (90%) (p less than 0.05). Ninety per cent of the patients healed at one month were asymptomatic whereas 50% of the patients with incomplete healing still had symptoms, most often dysphagia, rarely heartburn. Maintenance treatment with 20 mg was sufficient in most patients, with a probability of remaining healed of 69% from 9 to 24 months after starting this dosage. In 9 patients with Barrett's oesophagus, the lengths of the circumferential metaplasia were found to be reduced after one year of treatment compared to pre-trial lengths (p less than 0.005). There was no further significant reduction of length after 2 years of treatment. Fasting gastrin was increased in most of the patients, although great inter-patient variability was observed; 50% of the patients had levels not exceeding 5 times the upper limit of normal. There was no consistent increase of enterochromaffin-like cell density in 29 patients investigated up to nearly 2 years of omeprazole administration. The treatment was well tolerated. By inducing a profound and sustained inhibition of acid secretion, as confirmed by pH monitoring, omeprazole promotes healing of the lesions of severe oesophagitis and prevents recurrence of lesions and symptoms. Omeprazole is therefore a valuable treatment for patients ineligible for surgery, particularly in the elderly.
Authors:
R Fiasse; P Druez; J P Coppens; M Delhaze; C Fabre; S Pauwels; C Dive
Related Documents :
21743857 - Multiple facial plaques - a case study.
3532297 - Prevention of relapse with various antiulcer drugs.
8047827 - Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease.
2667937 - Ranitidine. an updated review of its pharmacodynamic and pharmacokinetic properties and...
23830717 - Predicting discharge outcomes after total knee replacement using the risk assessment an...
20464617 - Greater occipital nerve block in chronic migraine.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Acta gastro-enterologica Belgica     Volume:  53     ISSN:  0001-5644     ISO Abbreviation:  Acta Gastroenterol. Belg.     Publication Date:    1990 Sep-Dec
Date Detail:
Created Date:  1991-11-21     Completed Date:  1991-11-21     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0414075     Medline TA:  Acta Gastroenterol Belg     Country:  BELGIUM    
Other Details:
Languages:  eng     Pagination:  573-84     Citation Subset:  IM    
Affiliation:
Service de Gastro-entérologie, Cliniques St-Luc, Université Catholique de Louvain, Bruxelles.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Esophagitis, Peptic / classification,  drug therapy*,  metabolism
Female
Gastrins / blood
Humans
Hydrogen-Ion Concentration
Longitudinal Studies
Male
Middle Aged
Omeprazole / therapeutic use*
Chemical
Reg. No./Substance:
0/Gastrins; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Barrett's esophagus. Characterization and monitoring policy
Next Document:  The Belsey Mark IV antireflux procedure: indications and long-term results.